A new trading day began on Tuesday, with Ionis Pharmaceuticals Inc (NASDAQ: IONS) stock price down -1.61% from the previous day of trading, before settling in for the closing price of $40.36. IONS’s price has ranged from $35.95 to $54.44 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 13.97%. Meanwhile, its annual earnings per share averaged -40.18%. With a float of $145.55 million, this company’s outstanding shares have now reached $157.71 million.
Let’s determine the extent of company efficiency that accounts for 927 employees. In terms of profitability, gross margin is 97.22%, operating margin of -44.85%, and the pretax margin is -43.37%.
Ionis Pharmaceuticals Inc (IONS) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Ionis Pharmaceuticals Inc is 7.71%, while institutional ownership is 90.06%. The most recent insider transaction that took place on Oct 16 ’24, was worth 2,031. In this transaction EVP Research of this company sold 53 shares at a rate of $38.31, taking the stock ownership to the 157 shares. Before that another transaction happened on Aug 29 ’24, when Company’s EVP, Chief Development Officer sold 331 for $49.63, making the entire transaction worth $16,428. This insider now owns 84,823 shares in total.
Ionis Pharmaceuticals Inc (IONS) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around -40.18% per share during the next fiscal year.
Ionis Pharmaceuticals Inc (NASDAQ: IONS) Trading Performance Indicators
Here are Ionis Pharmaceuticals Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 7.51. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 7.69.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.53, a number that is poised to hit -1.13 in the next quarter and is forecasted to reach -3.42 in one year’s time.
Technical Analysis of Ionis Pharmaceuticals Inc (IONS)
Looking closely at Ionis Pharmaceuticals Inc (NASDAQ: IONS), its last 5-days average volume was 1.03 million, which is a drop from its year-to-date volume of 1.33 million. As of the previous 9 days, the stock’s Stochastic %D was 78.03%. Additionally, its Average True Range was 1.09.
During the past 100 days, Ionis Pharmaceuticals Inc’s (IONS) raw stochastic average was set at 17.67%, which indicates a significant decrease from 75.70% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 28.82% in the past 14 days, which was lower than the 40.76% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $42.13, while its 200-day Moving Average is $44.05. However, in the short run, Ionis Pharmaceuticals Inc’s stock first resistance to watch stands at $40.41. Second resistance stands at $41.12. The third major resistance level sits at $41.65. If the price goes on to break the first support level at $39.17, it is likely to go to the next support level at $38.64. Should the price break the second support level, the third support level stands at $37.93.
Ionis Pharmaceuticals Inc (NASDAQ: IONS) Key Stats
With a market capitalization of 6.26 billion, the company has a total of 146,211K Shares Outstanding. Currently, annual sales are 787,650 K while annual income is -366,290 K. The company’s previous quarter sales were 225,250 K while its latest quarter income was -66,270 K.
